Bone Marrow-on-Chip as smart sensor of lung cancer relapse
In the past 40 years the overall survival rate for people affected by tumors has doubled, with about 50% of patients now surviving their disease for 10 years or more. Nonetheless, some cancers (e.g lung cancer) still have poor sur...
In the past 40 years the overall survival rate for people affected by tumors has doubled, with about 50% of patients now surviving their disease for 10 years or more. Nonetheless, some cancers (e.g lung cancer) still have poor survival rate. A major cause of lung cancer mortality is represented by disease relapse, occuring when few of the original cancer cells survive the initial treatment and causing primary tumor recurrence. Currently, no options are available to predict the risk of lung cancer relapse, which is only diagnosed late based on radiological evidence. Hence, the ability to early detect lung cancer relapse represents an urgent and unmet need, since a fast and tailored treatment could dramatically increase patients’ survival rate.BuonMarrow lays on the groundbreaking hypothesis, supported by our Consortium preliminary clinical evidence, that bone marrow mesenchymal stromal cells (BM-MSC) may be educated upon cancer mediators exposure, and acquire a long-term memory-like response which is amplified when exposed to a secondary tumor. Owing to breakthrough technologies available in the Consortium (organ-on-chip, innovative optical sensors and biological modeling of the bone marrow niche), BuonMarrow partners will develop an in vitro miniaturized bone marrow device able to harness the amplified BM-MSC response generated by liquid biopsy of lung cancer patients, thus acting as a biological sensor for the early detection of relapse. A combination of retrospective and prospective clinical studies, respectively, will allow to calibrate and validate such sensor, delivering an unprecedented tool to assist the decision-making process on lung cancer patients.We expect to significantly improve oncological treatments, building on a personalized medicine approach to increased patient survival and well-being, and thereby deeply impacting on EU’s socio/economic environment.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.